Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Key facts

Sponsor

CSL Behring

Principal Investigator

Alex Veldman

CSL Behring

Intervention

Eptacog alfa (activated) or pdFVII(biological)

Enrollment

9 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2016

Study locations (2)

• Site Reference 5280023, Njmegen, Netherlands
• Site Reference # 5780001, Oslo, Norway

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital factor VII deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07347249
  A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
  Hemab ApS
• RECRUITINGPHASE1NCT06349473
  A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
  Equilibra Bioscience LLC

See all trials for Congenital factor VII deficiency →